ADC Therapeutics SA (ADCT) Tops Q4 EPS by 20c

ADC Therapeutics SA (NYSE: ADCT) reported Q4 EPS of ($0.09), $0.20 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $23.06 million versus the consensus estimate of $19.11 million.

For earnings history and earnings-related data on ADC Therapeutics SA (ADCT) click here.

You May Also Be Interested In

• Lyntris opens at $15.50, below IPO price of $17.50
• Lowe's slashes full-year sales outlook amid DIY spending pressure
• Trump: nominate Heidi Overton, MD, PhD, as our next FDA commissioner